The Top 5 Biosimilar Articles for the Week of September 27

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of September 27, 2021.

Number 5: The first ranibizumab biosimilar (Byooviz) has potential to alleviate financial burden associated with retinal conditions, but may not be the only new approval for ophthalmology treatment coming, explained Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars for Cardinal Health.

Number 4: Reykjavik, Iceland company Alvotech said the FDA review of its adalimumab candidate is being held up by pandemic-related curbs on overseas inspections.

Number 3: The month of September 2021 was chock-full of biosimilar news. From regulatory actions to policy initiatives to clinical news, no dust was gathered on the road toward wider biosimilar adoption.

Number 2: In a biosimilar trend report, Amgen discussed marketing achievements; US biosimilar policy, payer, and provider acceptance of these agents; and the outlook for further growth.

Number 1: The Center for Biosimilars® spoke with George Williams, MD, clinical spokesperson for the American Academy of Ophthalmology (AAO), about the FDA’s recent approval of Byooviz (ranibizumab), the first biosimilar specifically approved for treatment of eye diseases.

To read all of these articles and more, visit centerforbiosimilars.com.